Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 12, 2025World Journal of Gastrointestinal Oncology

Yttrium-90 microsphere therapy for hepatocellular carcinoma: Clinical efficacy, mechanistic insights, and comparative therapeutic perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYuhang ZhuMWMingwei WangYJYan Jiao

Discussion

Loading...

Member takes

Overview

Review demonstrates improved survival rates and tumor response in hepatocellular carcinoma with yttrium-90 therapy, highlighting its advantages over conventional treatments.

Key Points

  • Yttrium-90 microsphere therapy significantly improves overall survival and progression-free survival in hepatocellular carcinoma patients.
  • Robust tumor response rates are observed, with manageable adverse events associated with yttrium-90 therapy.
  • Advanced dosimetric techniques enhance the therapy's precision, tailoring radiation delivery to individual tumor characteristics.
  • Comparative analyses indicate yttrium-90 therapy offers superior local tumor control and a safer profile compared to traditional treatments.

Cite This Study

Zhu et al. (2025) studied this question.

synapsesocial.com/papers/689a02afe6551bb0af8cbeadhttps://doi.org/10.4251/wjgo.v17.i7.109379
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Overview of Yttrium-90 radioembolization for advanced hepatocellular carcinoma: Current status and future perspectives2025
  2. 2Harnessing yttrium-90 selective internal radiation therapy for primary hepatocellular carcinoma: Mechanisms of action and combination strategies2025
  3. 3Transarterial Radioembolization for Hepatocellular Carcinoma in Korea: Current Clinical Practices, Facility Requirements, and Patient Selection2025 · 1 citations
  4. 4Dose–response relationship in patients who received transarterial radioembolization with Y-90 resin microspheres for hepatocellular carcinoma2025
  5. 5Contemporary Clinical Utilization of Radioembolization with Immune Checkpoint Inhibitors as First-Line Treatment in HCC: Real-World Report on Safety and Outcomes2025